Redeye returns with an update following Ascelia Pharma's Q4 update, which contained no material surp...
* 0%/-3% adj. EBITDA vs ABGSCe/Infront cons in Q4 * Cons estimates likely flat on adj.
Redeye comments on Hacksaw ahead of Q4-results (due 17 February) where we expect continued solid gro...
Inderes's Q4 profitability was slightly ahead of our estimate, owing to slightly better than expecte...
The Leipurin segment was divested in August 2025 and ESL Shipping could be sold this year.
Investors House's Q4 report was solid, with the Services segment surprising positively, while the Re...
* We expect broad-based organic growth * Q4e net sales of SEK 193m, EBITA of SEK 25m * We reiterate ...
* FY'25e adj. EBIT NOK 81m * Accretive acquisition * Fair value range of NOK 15-25 '25e adj.
We expect a noticeable improvement in Gofore’s margin performance in Q4.
Gullberg & Jansson redovisade ökad nettoomsättning och minskad EBIT i det fjärde kvartalet.
Ahead of Atria's Q4 report, we maintain our estimates intact.
Redeye leaves its Base Case unchanged following Freja’s Q4 report.
Hyresintäkterna steg 49% till 61,7 MEUR tack vare stora polska förvärv, högre uthyrning och indexeri...
Angler Gaming väntas presentera sitt bokslut den 19 februari 2026 med ett utgångsläge som ser mer st...
Redeye provides a short comment on the Q4 report. We also highligt that following the acquisitions o...
Etteplan is set to report its Q4 figures on February 12.
YIT as expected saw a return to growth in Q4 and healthy profitability figures.
Redeye comments on the full recruitment of the phase IIb ADVANCE study in RA with 240 patients.
Redeye updates its estimates and valuation after Lagercrantz’s Q3 2025/2026 report.
Duni’s Q4 came in on the softer side, with FX headwinds and weak organic growth weighing on earnings...
